Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study

References

• WardSKingTChauhanNPooled analysis of time to administration of glucarpidase for methotrexate toxicitiy versus mortalityClin Toxicol2013517577578
   Google Scholar
• FlombaumCDLiuDYanSQManagement of patients with acute methotrexate nephrotoxicity with high-dose leucovorinPharmacotherapy Epub201864
   PubMedGoogle Scholar
• BuchenSNgampoloDMeltonRGCarboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failureBr J Cancer200592348048715668713
   PubMed Web of Science ®Google Scholar
• WidemannBCBalisFMKimAGlucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcomeJ Clin Oncol201028253979398620679598
   PubMed Web of Science ®Google Scholar
• WidemannBCJayaprakashNHowardSCClinical trial and compassionate use experience with glucarpidase for methotrexate toxicityJ Oncol Pharm Pract2014202 SUPPL. 189
   Google Scholar
• SchwartzSBornerKMüllerKGlucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapyOncologist200712111299130818055849
   PubMed Web of Science ®Google Scholar
• PattersonDMLeeSMGlucarpidase following high-dose methotrexate: update on developmentExpert Opin Biol Ther201010110511119925307
   PubMed Web of Science ®Google Scholar
• GreenJMGlucarpidase to combat toxic levels of methotrexate in patientsTher Clin Risk Manag2012840341323209370
   PubMed Web of Science ®Google Scholar
• WidemannBCBalisFMKempf-BielackBHigh-dose methotrexate-induced nephrotoxicity in patients with osteosarcomaCancer2004100102222223215139068
   PubMed Web of Science ®Google Scholar
• FermianoMBergsbakenJKolesarJMGlucarpidase for the management of elevated methotrexate levels in patients with impaired renal functionAm J Health Syst Pharm2014711079379824780487
   PubMed Web of Science ®Google Scholar
• CavoneJLYangDWangAGlucarpidase intervention for delayed methotrexate clearanceAnn Pharmacother201448789790724742398
   PubMedGoogle Scholar
• de MiguelDGarcía-SuárezJMartínYGil-FernándezJJBurgaletaCSevere acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugsNephrol Dial Transplant200823123762376618779628
   PubMedGoogle Scholar
• MartinezALebrunJClarivetBEffect of glucarpidase on methotrexate levels and renal function: about five casesFundam Clin Pharmacol201731Supplement 159
   Google Scholar
• NowickiTSBjornardKKudlowitzDSandovalCJayaboseSEarly recognition of renal toxicity of high-dose methotrexate therapyJ Pediatr Hematol Oncol2008301295095219131789
   PubMedGoogle Scholar
• WyattKDCooperJScottKDelayed methotrexate clearance despite carboxypeptidase-G2 (glucarpidase) administration in 2 patients with toxic methotrexate levelsJ Pediatr Hematol Oncol201840215215529240024
   PubMedGoogle Scholar
• ParkESHanKHChoiHSShinHYAhnHSCarboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicityCancer Res Treat200537213313519956493
   PubMedGoogle Scholar
• VilayAMMuellerBAHainesHAltenJAAskenaziDJTreatment of methotrexate intoxication with various modalities of continuous extra-corporeal therapy and glucarpidasePharmacotherapy201030111120030480
   PubMedGoogle Scholar
• SnyderRLResumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 useAm J Health Syst Pharm200764111163116917519458
   PubMedGoogle Scholar
• ConnorsNJSiseMENelsonLSHoffmanRSSmithSWMethotrexate toxicity treated with continuous venovenous hemofiltration and leucovorinClin Toxicol2013514366367
   Google Scholar
• GregianinLJde Castro JuniorCGEickRBrunettoALSuccessful management of acute renal failure after high-dose methotrexate in a patient with relapsed osteosarcomaAm J Case Rep200899396
   Google Scholar
• SharmaMVuppalliMAbroZBuffingtonM284 Methotrexate nephrotoxicity: is there a case for hemodialysis in the CPDG2 era?Am J Kidney Dis2011574B87
   Google Scholar
• TrifilioSMaSPetrichAReduced-dose carboxypeptidase-G2 successfully lowers elevated methotrexate levels in an adult with acute methotrexate-induced renal failureClin Adv Hematol Oncol201311532232323880719
   PubMedGoogle Scholar
• RamamoorthySKHephzibaRAcute renal failure post high dose methotrexate infusion successfully managed with high dose folinic Acid and high flux dialysisIndian J Hematol Blood Transfus2013292909224426345
   PubMedGoogle Scholar
• TuffahaHWAl OmarSGlucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicityJ Oncol Pharm Pract201117213614019833686
   PubMedGoogle Scholar
• BoelensADMathôtRAAVlaarAPJBoumanCSCGlucarpidase treatment for methotrexate intoxication: a case report and review of the literatureNeth J Med2018761363929380731
   PubMed Web of Science ®Google Scholar
• SalandJMLeaveyPJBashROHanschEArbusGSQuigleyREffective removal of methotrexate by high-flux hemodialysisPediatr Nephrol2002171082582912376811
   PubMed Web of Science ®Google Scholar
• HarmsJKhawajaATaylorMHanXMrugMRecovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapySAGE Open Med Case Rep20175 2050313X1770505
   PubMedGoogle Scholar
• GrosjeanFSepeVGottiMRossiMdal CantonAMethotrexate renal clearance by low-dose dopamine in severe nephrotoxicityRen Fail201638336236326726849
   PubMed Web of Science ®Google Scholar
• HowardSCMcCormickJPuiCHBuddingtonRKHarveyRDPreventing and managing toxicities of high-dose methotrexateOncologist201621121471148227496039
   PubMed Web of Science ®Google Scholar
• PitmanSWParkerLMTattersallMHClinical trial of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590)-toxicologic and therapeutic observationsCancer Chemother Rep197564349
   Google Scholar
• Von HoffDDPentaJSHelmanLJSlavikMIncidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administrationCancer Treat Rep1977614745748301783
   PubMedGoogle Scholar
• GlezermanIGJaimesEAChapter 11. Chemotherapy and kidney injuryAmerican Society of Nephrology.New York (NY)Onco-Nephrology2016110
   Google Scholar
• SilverSASiewEDFollow-up care in acute kidney injury: lost in transitionAdv Chronic Kidney Dis201724424625228778365
   PubMedGoogle Scholar
• Arias-CabralesCRodríguezEBermejoSShort- and long-term outcomes after non-severe acute kidney injuryClin Exp Nephrol2018221616728551821
   PubMedGoogle Scholar
• ParkESHanKHChoiHSShinHYAhnHSCarboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicityCancer Res Treat200537213313519956493
   PubMedGoogle Scholar
• HarmsJKhawajaATaylorMHanXMrugMRecovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapySAGE Open Med Case Rep20175 2050313X1770505
   PubMedGoogle Scholar
• MeyersPAFlombaumCHigh-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?J Clin Oncol2011297e18021220601
   PubMedGoogle Scholar
• WidemannBCAdamsonPCReply to P.A. Meyers et alJ Clin Oncol2011297e181
   PubMedGoogle Scholar
• WallSMJohansenMJMolonyDADuboseTDJaffeNMaddenTEffective clearance of methotrexate using high-flux hemodialysis membranesAm J Kidney Dis19962868468548957036
   PubMed Web of Science ®Google Scholar
• VoraxazeFDA Label (n.d.)2012 Available from: https://www.access-data.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdfAccessed January 3, 2019
   Google Scholar
• WidemannBCSchwartzSJayaprakashNEfficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapyPharmacotherapy201434542743924132809
   PubMed Web of Science ®Google Scholar
• WidemannBCAdamsonPCUnderstanding and managing methotrexate nephrotoxicityOncologist200611669470316794248
   PubMed Web of Science ®Google Scholar
• RamseyLBalisFMO’BrienMMConsensus guidelines for the use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearanceOncologist2018231526129079637
   PubMed Web of Science ®Google Scholar
• GrommesCDeAngelisLMPrimary CNS lymphomaJ Clin Oncol201735212410241828640701
   PubMed Web of Science ®Google Scholar
• RubensteinJLGuptaNKMannisGNLamarreAKTreselerPHow I treat CNS lymphomasBlood2013122142318233023963042
   PubMed Web of Science ®Google Scholar
• BlayJYConroyTChevreauCHigh-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective seriesJ Clin Oncol19981638648719508167
   PubMed Web of Science ®Google Scholar
• Yale New Haven Health Services Corporation/Center for Outcomes Research & Evaluation (YNHHSC/CORE)2015 Measure Updates and Specifications Report: Hospital-Wide All-Cause Unplanned Readmission Measure – Version 4.02015b Available from: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228774371008Accessed July 1, 2016
   Google Scholar
• ElixhauserASteinerCHarrisDRCoffeyRMComorbidity measures for use with administrative dataMed Care19983618279431328
   PubMed Web of Science ®Google Scholar
• AustinPCAn introduction to propensity score methods for reducing the effects of confounding in observational studiesMultivariate Behav Res201146339942421818162
   PubMed Web of Science ®Google Scholar
• AustinPCStuartEAMoving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studiesStat Med201534283661367926238958
   PubMed Web of Science ®Google Scholar
• StuartEALeeBKLeacyFPPrognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness researchJ Clin Epidemiol2013668 SupplS84S90.e123849158
   PubMed Web of Science ®Google Scholar
• GarridoMMKelleyASParisJMethods for constructing and assessing propensity scoresHealth Serv Res20144951701172024779867
   PubMed Web of Science ®Google Scholar